Ocugen Inc OCGN shares gained 13.71% to $8.71 Thursday after the company announced it's on track to submit its Emergency Use Authorization application to the FDA for its COVID-19 vaccine candidate COVAXIN.
Ocugen is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.
Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.
Ocugen's product candidate includes OCU200 and OCU300 to treat diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
